Pentixapharm Holding AG Logo

Pentixapharm Holding AG

PTP | F

Overview

Corporate Details

ISIN(s):
DE000A383RV0 (+1 more)
LEI:
3912005VBOVXNDXEQZ36
Country:
Germany
Address:
Robert-Rössle-Straße, 10, 13125 Berlin
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Pentixapharm Holding AG is a clinical-stage biopharmaceutical company specializing in the research and development of first-in-class radiopharmaceuticals. The company develops innovative compounds for both diagnostic and therapeutic (theranostic) applications, primarily targeting oncological indications such as blood cancers (hemato-oncology), solid tumors, and adrenal disorders. Its pipeline features two Phase III-ready drug candidates and a well-studied CXCR4 compound platform. With a strong focus on research and development, employing over 80% of its staff in R&D, the company's compounds have been administered to more than 2,000 patients through various clinical programs.

Social Media

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Pentixapharm Holding AG. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-06 00:00
Interim Report
Half-yearly financial report 2025
English 723.4 KB
2025-07-24 14:04
Report Publication Announcement
English 3.9 KB
2025-05-27 09:43
Regulatory News Service
Pentixapharm Holding AG: Pentixapharm outlines new clinical development strategy
English 10.0 KB
2025-05-08 00:00
Quarterly Report
Q1 statement / Q1 financial report 2025
English 479.2 KB
2025-04-26 16:00
Report Publication Announcement
English 3.8 KB
2025-04-25 00:00
Annual Report
Annual financial report 2024
English 2.3 MB
2025-04-24 14:00
Regulatory News Service
Pentixapharm Signs Contract Manufacturing Agreement for Yttrium-90-based Pentix…
English 8.8 KB
2025-04-17 15:05
Pre-Annual General Meeting Information
Pentixapharm Holding AG: Bekanntmachung der Einberufung zur Hauptversammlung am…
German 88.5 KB
2025-04-15 08:17
Report Publication Announcement
Pentixapharm Holding AG Releases Financial Results for 2024 and Announces Guida…
English 6.4 KB
2025-03-19 13:20
Report Publication Announcement
English 3.9 KB
2025-03-18 13:20
Report Publication Announcement
English 3.9 KB
2025-03-04 14:38
Board/Management Information
Changes in the Supervisory Board and Management Board of Pentixapharm Holding AG
English 6.4 KB
2025-03-03 14:38
Board/Management Information
Changes in the Supervisory Board and Management Board of Pentixapharm Holding AG
English 6.4 KB
2025-02-14 14:10
Regulatory News Service
First-In-Human Data about the Treatment of Muscle-Invasive Bladder Cancer with …
English 7.5 KB
2025-02-13 14:10
Regulatory News Service
First-In-Human Data about the Treatment of Muscle-Invasive Bladder Cancer with …
English 7.5 KB

Automate Your Workflow. Get a real-time feed of all Pentixapharm Holding AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Pentixapharm Holding AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
1NKEMIA Logo
Offers contract R&D, develops tech platforms, and invests in life sciences ventures.
Spain IKM
2cureX AB Logo
Tests cancer drugs on patient-derived micro-tumors for personalized oncology treatments.
Sweden 2CUREX
4SC AG Logo
Developing epigenetic small-molecule drugs for cancers with high unmet medical needs.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using an OMV platform for major infectious diseases.
Sweden ABERA
ABIVAX Logo
Developing oral drugs for chronic inflammatory diseases like ulcerative colitis and Crohn's disease.
France ABVX
Abliva Logo
A clinical-stage biotech developing medicines for rare primary mitochondrial diseases.
Sweden ABLI
Achiko AG Logo
A liquidated health tech firm that developed aptamer diagnostics and a COVID-19 passport app.
Switzerland ACHI
Acticor Biotech Logo
Biopharma developing first-in-class drugs for acute stroke and other thrombotic diseases.
France ALACT
Active Biotech Logo
Develops immunotherapies for cancer and inflammatory diseases with significant unmet needs.
Sweden ACTI
Addex Therapeutics Ltd Logo
Develops oral small molecule drugs, allosteric modulators, for neurological disorders.
Switzerland ADXN